Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) on Thursday announced the launch of Prucalopride Tablets, a generic version of Motegrity.
The US Food and Drug Administration (FDA) has granted ANI 180-day marketing exclusivity for its Prucalopride Tablets.
This launch follows the FDA's approval of ANI's Abbreviated New Drug Application (ANDA).
ANI's Prucalopride Tablets are expected to compete in a market with approximately USD168m in annual sales.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream